Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

Investors may react cautiously to news that TORNTPHARM's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 1.396000
forwardPE 41.999935
debtToEquity 33.400000
earningsGrowth 0.305000
revenueGrowth 0.143000
grossMargins 0.756870
operatingMargins 0.266200
trailingEps 63.290000
forwardEps 0.000000

Torrent Pharmaceuticals Limited's current ratio being 1.396 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Torrent Pharmaceuticals Limited can meet its financial obligations with ease.
TORNTPHARM's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with TORNTPHARM expected to continue increasing its profits and revenue in the coming periods.
Torrent Pharmaceuticals Limited's positive gross and operating margins suggest strong profitability. These margins reflect effective cost management and revenue generation, indicating that the company is efficiently managing its operations and maintaining financial health.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

TORNTPHARM's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about TORNTPHARM's ability to grow.

Insider Transactions:

Insider Transactions for TORNTPHARM
Insider Transactions for TORNTPHARM


1 transactions to buy TORNTPHARM took place, with market price at 3224.449951171875 per share.No buy transactions occurred during the period under consideration.TORNTPHARM's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


Analysts' buy bias toward Torrent Pharmaceuticals Limited suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Torrent Pharmaceuticals Limited is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.